One Shot™ BL21(DE3)pLysS Chemically Competent E. coli
본 제품은 LMO 제품으로, 고객 분께서 LMO 신고 시스템을 통해 직접 수입 신고를 진행해주셔야 합니다. 자세히보기
One Shot&trade; BL21(DE3)pLysS Chemically Competent <i>E. coli</i>
Invitrogen™

One Shot™ BL21(DE3)pLysS Chemically Competent E. coli

BL21(DE3)pLysS cell은 T7 promoter-based expression systems (예:, pRSET, pCR™T7, pET)에 사용하는데 이상적입니다. BL21(DE3)pLysS E. coli 에는 DE3 lysogen와 plasmid pLysS가자세히 알아보기
Have Questions?
보기 방식 변경buttonViewtableView
카탈로그 번호수량
C60600321 x 50 μL Tubes
C60601011 x 50 μL/tube
카탈로그 번호 C606003
제품 가격(KRW)
536,000
キャンペーン価格
Ends: 31-Mar-2026
612,000
할인액 76,000 (12%)
Each
카트에 추가하기
수량:
21 x 50 μL Tubes
제품 가격(KRW)
536,000
キャンペーン価格
Ends: 31-Mar-2026
612,000
할인액 76,000 (12%)
Each
카트에 추가하기
BL21(DE3)pLysS cell은 T7 promoter-based expression systems (예:, pRSET, pCR™T7, pET)에 사용하는데 이상적입니다. BL21(DE3)pLysS E. coli 에는 DE3 lysogen와 plasmid pLysS가 모두 들어있습니다. pLysS는 본질적으로 T7 lysozyme 발현 수준이 낮아 T7 RNA polymerase의 기본 발현 수준을 억제하며 재조합 유전자의 기본 발현을 낮춥니다.
For Research Use Only. Not for use in diagnostic procedures.
사양
항생제 내성 박테리아Yes (Chloramphenicol)
블루/화이트 스크리닝No
메틸화 DNA 클로닝No
에프에피솜 포함No
고처리량 호환성Low
플라스미드 품질 개선No
Improves Protein StabilityYes (lon, ompT)
Improves RNA StabilityYes (pLysS)
비메틸화 DNA 준비Yes (dcm)
제품라인One Shot
제품 유형Chemically Competent Cells
수량21 x 50 μL Tubes
재조합 감소No
배송 조건Dry Ice
T1 Phage - 저항성(tonA)No
Toxic ProteinsNo
형질전환 효율 수준Medium Efficiency (1 x 108 to 1 x 109 cfu/μg)
형식Tube
프로모터T7
E. coli (B)
Unit SizeEach
구성 및 보관
• Chemically Competent cells (21 x 50 μL); store at –80°C
• pUC19 Control DNA (1 x 50 μL); store at –80°C
• S.O.C. Medium (6 mL); store at 4°C or room temperature

자주 묻는 질문(FAQ)

My gene of interest is toxic to bacterial cells. Are there any precautions you can suggest?

Several precautions may be taken to prevent problems resulting from basal level expression of a toxic gene of interest. These methods all assume that the T7-based or Champion-based expression plasmid has been correctly designed and created.

- Propagate and maintain your expression plasmid in a strain that does not contain T7 RNA polymerase (i.e., DH5α).
- If using BL21 (DE3) cells, try growing cells at room temperature rather than 37 degrees C for 24-48 hr.
- Perform a fresh transformation using a tightly regulated E. coli strain, such as BL21-AI cells.
- After following the transformation protocol, plate the transformation reaction on LB plates containing 100 µg/mL ampicillin and 0.1% glucose. The presence of glucose represses basal expression of T7 RNA polymerase.
- Following transformation of BL21-AI cells, pick 3 or 4 transformants and inoculate directly into fresh LB medium containing 100 µg/mL ampicillin or 50 µg/mL carbenicillin (and 0.1% glucose, if desired). When the culture reaches an OD600 of 0.4, induce expression of the recombinant protein by adding L-arabinose to a final concentration of 0.2%.
- When performing expression experiments, supplement the growth medium with 0.1% glucose in addition to 0.2% arabinose.
- Try a regulated bacterial expression system such as our pBAD system.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I'm trying to express my protein using a bacterial expression system. How do I know if I'm seeing degradation of my protein or if what I’m seeing is codon usage bias?

Typically, if you see 1-2 dominant bands, translation stopped prematurely due to codon usage bias. With degradation, you usually see a ladder of bands. With degradation, you can try using a protease inhibitor and add it to the lysis buffer to help prevent degradation. If degradation is the issue, a time point experiment can be done to determine the best time to harvest the cells.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I'm trying to express my protein using a bacterial expression system and am getting inclusion bodies. What should I do?

If you are having a solubility issue, try to decrease the temperature or decrease the amount of IPTG used for induction. You can also try a different, more stringent cell strain for expression. Adding 1% glucose to the bacterial culture medium during expression can also help.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I'm getting low protein yield from my bacterial expression system. What can I do to improve this?

- Inoculate from fresh bacterial cultures, since higher protein yields are generally obtained from a fresh bacterial colony.

- Check the codon usage in the recombinant protein sequence for infrequently used codons. Replacing the rare codons with more commonly used codons can significantly increase expression levels. For example, the arginine codons AGG and AGA are used infrequently by E. coli, so the level of tRNAs for these codons is low.

- Add protease inhibitors, such as PMSF, to buffers during protein purification. Use freshly made PMSF, since PMSF loses effectiveness within 30 min of dilution into an aqueous solution.

- If you are using ampicillin for selection in your expression experiments, you may be experiencing plasmid instability due to the absence of selective conditions. This occurs as the ampicillin is destroyed by β-lactamase or hydrolyzed under the acidic media conditions generated by bacterial metabolism. You may want to substitute carbenicillin for ampicillin in your transformation and expression experiments.

- The recombinant protein may be toxic to bacterial cells. Try a tighter regulation system for competent cell expression such as BL21-AI. You may also consider trying a different expression system such as the pBAD system.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

My cells are growing very slowly, and I'm not getting any protein expression from my baterial expression system. What can I do to fix this?

This typically occurs when your gene of interest is toxic. Try using a tighter regulation system, such as BL21 (DE3) (pLysS) or BL21 (DE3) (pLysE), or BL21(AI).

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

인용 및 참조 문헌 (3)

인용 및 참조 문헌
Abstract
Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition.
Authors:Tribuddharat C, Moore RA, Baker P, Woods DE,
Journal:Antimicrob Agents Chemother
PubMed ID:12821450
'Burkholderia pseudomallei, the causative agent of melioidosis, is inherently resistant to a variety of antibiotics including aminoglycosides, macrolides, polymyxins, and beta-lactam antibiotics. Despite resistance to many beta-lactams, ceftazidime and beta-lactamase inhibitor-beta-lactam combinations are commonly used for treatment of melioidosis. Here, we examine the enzyme kinetics of beta-lactamase isolated from mutants ... More
Characterization of the interaction between P143 and LEF-3 from two different baculovirus species: Choristoneura fumiferana nucleopolyhedrovirus LEF-3 can complement Autographa californica nucleopolyhedrovirus LEF-3 in supporting DNA replication.
Authors:Chen T, Sahri D, Carstens EB,
Journal:J Virol
PubMed ID:14671115
The baculovirus protein P143 is essential for viral DNA replication in vivo, likely as a DNA helicase. We have demonstrated that another viral protein, LEF-3, first described as a single-stranded DNA binding protein, is required for transporting P143 into the nuclei of insect cells. Both of these proteins, along with ... More
Recognition of nonhybridizing base pairs during nucleotide excision repair of DNA.
Authors:Buschta-Hedayat N, Buterin T, Hess MT, Missura M, Naegeli H
Journal:Proc Natl Acad Sci U S A
PubMed ID:10339546
Nondistorting C4' backbone adducts serve as molecular tools to analyze the strategy by which a limited number of human nucleotide excision repair (NER) factors recognize an infinite variety of DNA lesions. We have constructed composite DNA substrates containing a noncomplementary site adjacent to a nondistorting C4' adduct to show that ... More